Shanghai Kaibao Pharmaceutical CO.,Ltd (SHE:300039)
China · Delayed Price · Currency is CNY 6.21
+0.06 (0.98%)
Feb 3, 2026, 3:07 PM CST
SHE:300039 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,169 | 1,471 | 1,591 | 1,117 | 1,099 | 907.1 |
Other Revenue | 1.9 | 1.9 | 3.03 | 2.25 | 1.29 | 0.91 |
| 1,171 | 1,473 | 1,594 | 1,119 | 1,101 | 908.01 | |
Revenue Growth (YoY) | -24.98% | -7.57% | 42.47% | 1.66% | 21.21% | -36.01% |
Cost of Revenue | 221.04 | 272.96 | 311.82 | 247.85 | 234.1 | 180.55 |
Gross Profit | 950.07 | 1,200 | 1,282 | 871 | 866.48 | 727.46 |
Selling, General & Admin | 563.08 | 727.1 | 858.13 | 612.86 | 652.66 | 583.45 |
Research & Development | 60.79 | 99.79 | 95.87 | 52.97 | 79.32 | 59.12 |
Other Operating Expenses | 20.96 | 22.76 | 23.92 | 16.92 | 11.5 | 8.2 |
Operating Expenses | 641.43 | 845.49 | 972.48 | 689.51 | 747.13 | 647.45 |
Operating Income | 308.65 | 354.87 | 309.75 | 181.49 | 119.35 | 80.01 |
Interest Expense | -0.1 | -0.04 | - | - | -0.15 | -0.52 |
Interest & Investment Income | 71.24 | 64.5 | 60.87 | 42.66 | 44.77 | 50.93 |
Other Non Operating Income (Expenses) | 0.23 | 0.04 | -0.57 | -0.16 | -0.03 | -1.19 |
EBT Excluding Unusual Items | 380.02 | 419.37 | 370.05 | 224 | 163.94 | 129.23 |
Impairment of Goodwill | - | - | -9.04 | -4.75 | -4.71 | - |
Gain (Loss) on Sale of Investments | 4.61 | 1.1 | -4.54 | -6.59 | 1.8 | -12.14 |
Gain (Loss) on Sale of Assets | -0.2 | -0.26 | -0.21 | -0.17 | -0.22 | -0.07 |
Asset Writedown | -0.44 | -0.62 | -0.1 | - | - | - |
Other Unusual Items | 14.09 | 14.59 | 27.38 | 13.71 | 8.84 | 14.58 |
Pretax Income | 398.08 | 434.18 | 383.53 | 226.19 | 169.65 | 131.6 |
Income Tax Expense | 53.13 | 59.27 | 56.63 | 36.11 | 29.54 | 25.48 |
Earnings From Continuing Operations | 344.94 | 374.91 | 326.9 | 190.08 | 140.11 | 106.12 |
Minority Interest in Earnings | 0.61 | 0.67 | 0.97 | 0.72 | 0 | - |
Net Income | 345.55 | 375.58 | 327.87 | 190.8 | 140.11 | 106.12 |
Net Income to Common | 345.55 | 375.58 | 327.87 | 190.8 | 140.11 | 106.12 |
Net Income Growth | -0.94% | 14.55% | 71.84% | 36.18% | 32.03% | -57.72% |
Shares Outstanding (Basic) | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 |
Shares Outstanding (Diluted) | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 |
Shares Change (YoY) | -0.01% | 0.00% | -0.02% | 0.01% | 0.04% | -1.31% |
EPS (Basic) | 0.33 | 0.36 | 0.31 | 0.18 | 0.13 | 0.10 |
EPS (Diluted) | 0.33 | 0.36 | 0.31 | 0.18 | 0.13 | 0.10 |
EPS Growth | -0.93% | 14.54% | 71.88% | 36.17% | 31.97% | -57.16% |
Free Cash Flow | 201.66 | 138.43 | 353.59 | 344.8 | 83.53 | 236.71 |
Free Cash Flow Per Share | 0.19 | 0.13 | 0.34 | 0.33 | 0.08 | 0.23 |
Dividend Per Share | 0.130 | 0.100 | 0.100 | 0.060 | 0.050 | 0.030 |
Dividend Growth | 30.00% | - | 66.67% | 20.00% | 66.67% | -70.00% |
Gross Margin | 81.13% | 81.47% | 80.44% | 77.85% | 78.73% | 80.12% |
Operating Margin | 26.36% | 24.09% | 19.43% | 16.22% | 10.84% | 8.81% |
Profit Margin | 29.51% | 25.49% | 20.57% | 17.05% | 12.73% | 11.69% |
Free Cash Flow Margin | 17.22% | 9.40% | 22.18% | 30.82% | 7.59% | 26.07% |
EBITDA | 342.48 | 390.29 | 347.28 | 213.2 | 153.21 | 120.82 |
EBITDA Margin | 29.24% | 26.49% | 21.79% | 19.05% | 13.92% | 13.31% |
D&A For EBITDA | 33.84 | 35.42 | 37.53 | 31.71 | 33.86 | 40.81 |
EBIT | 308.65 | 354.87 | 309.75 | 181.49 | 119.35 | 80.01 |
EBIT Margin | 26.36% | 24.09% | 19.43% | 16.22% | 10.84% | 8.81% |
Effective Tax Rate | 13.35% | 13.65% | 14.77% | 15.96% | 17.41% | 19.36% |
Revenue as Reported | 1,171 | 1,473 | 1,594 | 1,119 | 1,101 | 908.01 |
Advertising Expenses | - | - | - | - | 11.24 | 7.07 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.